High impact of quadrivalent human papillomavirus vaccine across racial/ethnic groups: National Health and Nutrition Examination Survey, 2003–2006 and 2015–2018

References

• Lewis RM, Laprise JF, Gargano JW, Unger ER, Querec TD, Chesson HW, Brisson M, Markowitz LE. Estimated prevalence and incidence of disease-associated human papillomavirus types among 15- to 59-year-olds in the United States. Sex Transm Dis. 2021;48(4):273–5. doi:10.1097/OLQ.0000000000001356.
   PubMed Web of Science ®Google Scholar
• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664–70. doi:10.1002/ijc.30716.
   PubMed Web of Science ®Google Scholar
• Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24(Suppl 3):S3/35–41. doi:10.1016/j.vaccine.2006.06.015.
   PubMedGoogle Scholar
• Polite BN, Adams-Campbell LL, Brawley OW, Bickell N, Carethers JM, Flowers CR, Foti M, Gomez SL, Griggs JJ, Lathan CS. et al. Charting the future of cancer health disparities research: a position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. JCO. 2017;35(26):3075–82. doi:10.1200/JCO.2017.73.6546.
   PubMed Web of Science ®Google Scholar
• Perkins R, Mitchell E. Cervical cancer disparities. J Natl Med Assoc. 2023;115(2):S19–s25. doi:10.1016/j.jnma.2023.02.006.
   PubMed Web of Science ®Google Scholar
• Bailey ZD, Feldman JM, Bassett MT. How structural racism works — racist policies as a root cause of U.S. racial health inequities. N Engl J Med. 2021;384(8):768–73. doi:10.1056/NEJMms2025396.
   PubMed Web of Science ®Google Scholar
• Islami F, Guerra CE, Minihan A, Yabroff KR, Fedewa SA, Sloan K, Wiedt TL, Thomson B, Siegel RL, Nargis N. et al. American Cancer Society’s report on the status of cancer disparities in the United States, 2021. CA Cancer J Clin. 2022;72(2):112–43. doi:10.3322/caac.21703.
   PubMed Web of Science ®Google Scholar
• U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2022 submission data (1999-2020): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; https://www.cdc.gov/cancer/dataviz, released in November 2023.
   Google Scholar
• Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698–702. doi:10.15585/mmwr.mm6832a3.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Gee J, Chesson H, Stokley S. Ten Years of human papillomavirus vaccination in the United States. Acad Pediatr. 2018;18(2):S3–s10. doi:10.1016/j.acap.2017.09.014.
   PubMed Web of Science ®Google Scholar
• Rosenblum HG, Lewis RM, Gargano JW, Querec TD, Unger ER, Markowitz LE. Human papillomavirus vaccine impact and effectiveness through 12 years after vaccine introduction in the United States, 2003 to 2018. Ann Intern Med. 2022;175(7):918–26. doi:10.7326/M21-3798.
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. NHANES - About the National Health and Nutrition Examination Survey. [accessed 2023 Oct 3]. https://www.cdc.gov/nchs/nhanes/about_nhanes.htm.
   Google Scholar
• Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE. Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003–2006. J Infect Dis. 2011;204(4):566–73. doi:10.1093/infdis/jir341.
   PubMed Web of Science ®Google Scholar
• Rosenblum HG, Lewis RM, Gargano JW, Querec TD, Unger ER, Markowitz LE. Declines in prevalence of human papillomavirus vaccine-type infection among females after introduction of vaccine — United States, 2003–2018. MMWR Morb Mortal Wkly Rep. 2021;70(12):415–20. doi:10.15585/mmwr.mm7012a2.
   PubMed Web of Science ®Google Scholar
• McClung NM, Lewis RM, Gargano JW, Querec T, Unger ER, Markowitz LE. Declines in vaccine-type human papillomavirus prevalence in females across racial/ethnic groups: data from a national survey. J Adolesc Health. 2019;65(6):715–22. doi:10.1016/j.jadohealth.2019.07.003.
   PubMed Web of Science ®Google Scholar
• Brown DR, Joura EA, Yen GP, Kothari S, Luxembourg A, Saah A, Walia A, Perez G, Khoury H, Badgley D. et al. Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence. Vaccine. 2021;39(16):2224–36. doi:10.1016/j.vaccine.2020.11.076.
   PubMed Web of Science ®Google Scholar
• Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Fredua B, Singleton JA, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years — United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718–23. doi:10.15585/mmwr.mm6833a2.
   PubMed Web of Science ®Google Scholar
• Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JML, Cummings T. et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80. doi:10.1016/S1473-3099(14)71073-4.
   PubMed Web of Science ®Google Scholar
• Pingali C, Yankey D, Elam-Evans LD, Markowitz LE, Valier MR, Fredua B, Crowe SJ, DeSisto CL, Stokley S, Singleton JA. Vaccination coverage among adolescents aged 13–17 years — National Immunization Survey–Teen, United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(34):912–9. doi:10.15585/mmwr.mm7234a3.
   PubMed Web of Science ®Google Scholar